Enhancing endocrine response with novel targeted therapies.

The article discusses the combined use of signal transduction inhibitors (STIs) and endocrine therapies to enhance endocrine responsiveness and delay acquired resistance in the treatment of breast cancer. According to the author, many biological agents have been developed to target key proteins along the HER-2 and mitogen-activated protein kinases (MAPK) signal transduction cascades but their clinical trials have been unsuccessful.